1
|
Hu X, Li M, Xian Y, Liu X, Liu M, Li G, Hu P, Cheng C. Waterborne polyurethane‐based dye with covalently bonded to Disperse blue 60. J Appl Polym Sci 2019. [DOI: 10.1002/app.48862] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Xianhai Hu
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Mingjun Li
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Yuxi Xian
- CAS Key Laboratory for Mechanical Behavior and Design of MaterialsUniversity of Science and Technology of China Hefei 230026 People's Republic of China
| | - Xiang Liu
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Manli Liu
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Gen Li
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Pengwei Hu
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| | - Congliang Cheng
- Anhui Key Laboratory of Advanced Building Materials, School of Materials Science and Chemical EngineeringAnhui Jianzhu University Hefei 230601 People's Republic of China
| |
Collapse
|
2
|
Hu XH, Liu X, Liu ML, Li G. A waterborne polyurethane-based polymeric dye with covalently linked disperse red 11. REACT FUNCT POLYM 2018. [DOI: 10.1016/j.reactfunctpolym.2018.08.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Tapeinou A, Giannopoulou E, Simal C, Hansen BE, Kalofonos H, Apostolopoulos V, Vlamis-Gardikas A, Tselios T. Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP 85-99) epitope: Towards selective immunosuppression. Eur J Med Chem 2017; 143:621-631. [PMID: 29216561 DOI: 10.1016/j.ejmech.2017.11.063] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 09/14/2017] [Accepted: 11/22/2017] [Indexed: 02/09/2023]
Abstract
Anthraquinone type compounds, especially di-substituted amino alkylamino anthraquinones have been widely studied as immunosuppressants. The anthraquinone ring is part of mitoxandrone that has been used for the treatment of multiple sclerosis (MS) and several types of tumors. A desired approach for the treatment of MS would be the immunosuppression and elimination of specific T cells that are responsible for the induction of the disease. Herein, the development of a peptide compound bearing an anthraquinone derivative with the potential to specifically destroy the encephalitogenic T cells responsible for the onset of MS is described. The compound consists of the myelin basic protein (MBP) 85-99 immunodominant epitope (MBP85-99) coupled to an anthraquinone type molecule (AQ) via a disulfide (S-S) and 6 amino hexanoic acid (Ahx) residues (AQ-S-S-(Ahx)6MBP85-99). AQ-S-S-(Ahx)6MBP85-99 could bind to HLA II DRB1*-1501 antigen with reasonable affinity (IC50 of 56 nM) The compound was localized to the nucleus of Jurkat cells (an immortalized line of human T lymphocytes) 10 min after its addition to the medium and resulted in lowered Bcl-2 levels (apoptosis). Entrance of the compound was abolished when cells were pre-treated with cisplatin, an inhibitor of thioredoxin reductase. Accordingly, levels of free thiols were elevated in the culture supernatants of Jurkat cells exposed to N-succinimidyl 3-(2-pyridyldithio) propionate coupled to (Ahx)6MBP85-99 via a disulphide (SPDP-S-S-(Ahx)6MBP85-99) but returned to normal after exposure to cisplatin. These results raise the possibility of AQ-S-S-(Ahx)6MBP85-99 being used as an eliminator of encephalitogenic T cells via implication of the thioredoxin system for the generation of the toxic, thiol-containing moiety (AQ-SH). Future experiments would ideally determine whether SPDP-S-S-(Ahx)6MBP85-99 could incorporate into HLA II DRB1*-1501 tetramers and neutralize encephalitogenic T cell lines sensitized to MBP85-99.
Collapse
Affiliation(s)
- Anthi Tapeinou
- Department of Chemistry, University of Patras, GR-26504, Rion, Greece
| | - Efstathia Giannopoulou
- Clinical Oncology Laboratory, University Hospital of Patras, Patras Medical School, GR-26504, Rion, Greece
| | - Carmen Simal
- Department of Chemistry, University of Patras, GR-26504, Rion, Greece
| | - Bjarke E Hansen
- Institute for Inflammation Research, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen, Denmark
| | - Haralabos Kalofonos
- Clinical Oncology Laboratory, University Hospital of Patras, Patras Medical School, GR-26504, Rion, Greece
| | - Vasso Apostolopoulos
- Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia
| | | | - Theodore Tselios
- Department of Chemistry, University of Patras, GR-26504, Rion, Greece.
| |
Collapse
|
4
|
Heterocyclic analogs of 5,12-naphtacenequinone 13*. Synthesis of 4,11-diaminoanthra[2,3-b]furan-5,10-diones and sulfur-containing analogs. Chem Heterocycl Compd (N Y) 2016. [DOI: 10.1007/s10593-016-1968-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM. Mitoxantrone, More than Just Another Topoisomerase II Poison. Med Res Rev 2015; 36:248-99. [PMID: 26286294 DOI: 10.1002/med.21364] [Citation(s) in RCA: 119] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 07/13/2015] [Accepted: 07/14/2015] [Indexed: 02/06/2023]
Abstract
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is firmly established as a DNA topoisomerase II poison within mammalian cells, it is now clear that the drug interacts with a much broader range of biological macromolecules both covalently and noncovalently. Here, we consider each of these interactions in the context of their wider biological relevance to cancer therapy and highlight how they may be exploited to further enhance the therapeutic value of mitoxantrone. In doing so, it is now clear that mitoxantrone is more than just another topoisomerase II poison.
Collapse
Affiliation(s)
- Benny J Evison
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Victoria, 3086, Australia
| | - Brad E Sleebs
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.,Department of Medical Biology, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - Keith G Watson
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.,Department of Medical Biology, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - Don R Phillips
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Victoria, 3086, Australia
| | - Suzanne M Cutts
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Victoria, 3086, Australia
| |
Collapse
|
6
|
Su J, Zhang X, Dai J, Zhang J. Synthesis and Characterization of New Self-Colored Blue Waterborne Polyurethane Based on a Colorant Diol as Chain Extender. J DISPER SCI TECHNOL 2012. [DOI: 10.1080/01932691.2011.596329] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Alves CCS, Castro SBR, Costa CF, Dias AT, Alves CJ, Rodrigues MF, Teixeira HC, Almeida MV, Ferreira AP. Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis. Int Immunopharmacol 2012; 14:127-32. [PMID: 22749732 DOI: 10.1016/j.intimp.2012.06.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2012] [Revised: 06/06/2012] [Accepted: 06/16/2012] [Indexed: 11/29/2022]
Abstract
The present study investigated the effects of the anthraquinone derivative (O,O'-bis-(3'-iodopropyl)-1,4-dihidroxyanthraquinone - DIPDHAQ), mitoxantrone analog, in an experimental autoimmune encephalomyelitis (EAE) model. The results showed that DIPDHAQ treatment improved the clinical signs of the disease (n=10; vehicle: 3.8 ± 0.3; DIPDHAQ: 1.4 ± 0.9). The improvement was associated with a decrease of inflammatory cells, demyelination, IL-17, IFN-γ, IL-12p40, IL-6, TGF-β, CCL5 and CCL20 levels in the spinal cord. DIPDHAQ presented a low cytotoxicity when in vitro assays were performed. Therefore, the findings suggest a major role for DIPDHAQ in multiple sclerosis, disease characterized as an autoimmune inflammatory disorder against myelin proteins of the brain and spinal cord. The attenuation of inflammation and consequently improvement of clinical signs, involving a decrease of pro-inflammatory cytokines and the low cytotoxicity of DIPDHAQ, suggest that this compound could be used as an alternative treatment for autoimmune diseases in the central nervous system.
Collapse
Affiliation(s)
- Caio C S Alves
- Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, 36036-900 Juiz de Fora, Minas Gerais, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|